Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine

Frankenburg, Shoshana; Axelrod, Ofra; Kutner, Shirley; Greenblatt, Charles L.; Klaus, Sidney N.; Pirak, Esther Aboud; McMaster, Robert; Lowell, George H.

doi:10.1016/0264-410x(95)00245-v

Cited by 26 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a murine model of cutaneous leishmaniasis, immunisation in saline with a peptide representing a predicted CD4 + T cell epitope of gp63 significantly protected CBA mice against the development of severe cutaneous lesions only when the peptide was intrinsically adjuvanted by covalently adding a lauryl-cysteine moiety to its amino terminus. In marked contrast, administration of unlipidated peptide resulted in some disease exacerbation [89]. For vaccination against foot-and-mouth disease virus, seven lipopeptides encompassing linear B-cell epitopes were used to immunise cattle with four of seven animals showing protection from lesion development after challenge [90].…”

Section: Lipopeptides For the Induction Of T Cell Responsesmentioning

confidence: 99%

Lipid-based Self-Adjuvanting Vaccines

Brown¹,

Jackson

2005

CDD

View full text Add to dashboard Cite

Lipopeptides incorporating epitopes for CD4+ T cells and either CD8+ T cells or B cells have proven to be immunogenic in animal models and in humans and are well tolerated in these species. This form of vaccine candidate has great benefits over competing technology in terms of providing a totally synthetic and pure product that is effective when administered in the absence of any adjuvant, and is immunogenic when delivered by a variety of routes, including application to mucosal surfaces. The immune response can be focused on critical epitopes of the pathogen or tumour antigen to provide clearing immunity, and responses can also be invoked that modulate hormone activity. This review will cover examples of lipopeptides of different design and their efficacy in different systems as well as challenges for the future. Our recent understanding of how the lipid component confers the "self-adjuvanting" property on these immunogens by targeting the cell at the heart of immune response induction, the dendritic cell, will also be discussed.

show abstract

Section: Lipopeptides For the Induction Of T Cell Responsesmentioning

confidence: 99%

Lipid-based Self-Adjuvanting Vaccines

Brown¹,

Jackson

2005

CDD

View full text Add to dashboard Cite

show abstract

“…There is a clear segregation of the antigenicity and the immunogenicity of the peptides; only 3 of the 11 stimulatory peptides were able to induce a T-cell response as well as being recognized by T-cells from recovered mice. Frankenburg et al (118) also tested two peptides representing predicted T-cell epitopes of GP63 of L. major in vaccines tested in murine model of CL. Either subcutaneous (s.c.) or intraperitoneal (i.p.)…”

Section: Newer Alternative Strategies For Developing Anti-leishmanialmentioning

confidence: 99%

Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches

et al. 2014

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) or kala-azar, a vector-borne protozoan disease, shows endemicity in larger areas of the tropical, subtropical and the Mediterranean countries. WHO report suggested that an annual incidence of VL is nearly 200,000 to 400,000 cases, resulting in 20,000 to 30,000 deaths per year. Treatment with available anti-leishmanial drugs are not cost effective, with varied efficacies and higher relapse rate, which poses a major challenge to current kala-azar control program in Indian subcontinent. Therefore, a vaccine against VL is imperative and knowing the fact that recovered individuals developed lifelong immunity against re-infection, it is feasible. Vaccine development program, though time taking, has recently gained momentum with the emergence of omic era, i.e., from genomics to immunomics. Classical as well as molecular methodologies have been overtaken with alternative strategies wherein proteomics based knowledge combined with computational techniques (immunoinformatics) speed up the identification and detailed characterization of new antigens for potential vaccine candidates. This may eventually help in the designing of polyvalent synthetic and recombinant chimeric vaccines as an effective intervention measures to control the disease in endemic areas. This review focuses on such newer approaches being utilized for vaccine development against VL.

show abstract

“…The outcomes have been variable (3,42,84,106,126). Most of this work currently involves animal models, and the use of these systems in humans is still somewhat distant.…”

Section: Delivery and Adjuvantsmentioning

confidence: 99%

Leishmaniasis: Current Status of Vaccine Development

2001

View full text Add to dashboard Cite

Leishmaniae are obligatory intracellular protozoa in mononuclear phagocytes. They cause a spectrum of diseases, ranging in severity from spontaneously healing skin lesions to fatal visceral disease. Worldwide, there are 2 million new cases each year and 1/10 of the world's population is at risk of infection. To date, there are no vaccines against leishmaniasis and control measures rely on chemotherapy to alleviate disease and on vector control to reduce transmission. However, a major vaccine development program aimed initially at cutaneous leishmaniasis is under way. Studies in animal models and humans are evaluating the potential of genetically modified live attenuated vaccines, as well as a variety of recombinant antigens or the DNA encoding them. The program also focuses on new adjuvants, including cytokines, and delivery systems to target the T helper type 1 immune responses required for the elimination of this intracellular organism. The availability, in the near future, of the DNA sequences of the human and Leishmania genomes will extend the vaccine program. New vaccine candidates such as parasite virulence factors will be identified. Host susceptibility genes will be mapped to allow the vaccine to be targeted to the population most in need of protection

show abstract

Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine

Cited by 26 publications

References 28 publications

Lipid-based Self-Adjuvanting Vaccines

Lipid-based Self-Adjuvanting Vaccines

Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches

Leishmaniasis: Current Status of Vaccine Development

Contact Info

Product

Resources

About